<DOC>
	<DOCNO>NCT01396187</DOCNO>
	<brief_summary>This trial subject Type 2 diabetes mellitus study safety , tolerability pharmacokinetics multiple ascend dos PF-05231023 .</brief_summary>
	<brief_title>Safety Tolerability Ascending Intravenous Doses PF-05231023 In Adult Subjects With Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<criteria>Male subject female subject nonchildbearing potential age 30 70 year , inclusive , historical diagnosis type 2 diabetes mellitus , diagnose accord American Diabetes Association guideline . Subjects condition well control either diet medication may include well ( example , subject high cholesterol level appropriate treatment eligible ) . Body Mass Index ( BMI ) 25 35.5 kg/m2 , total body weight &gt; 50 kg ( 110 lb ) . Evidence history clinically significant hematological , renal , endocrine , pulmonary , gastrointestinal , cardiovascular , hepatic , psychiatric , neurologic , allergic disease ( include drug allergy , exclude untreated , asymptomatic , seasonal allergy time dose ) . Diagnosis Type 1 diabetes mellitus . Evidence diabetic complication significant end organ damage</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>Type 2 diabetes</keyword>
	<keyword>safety</keyword>
	<keyword>multiple dose</keyword>
	<keyword>intravenous</keyword>
</DOC>